Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

YOU WONT BELIEVE: 3 - You Need To See This

GBS: GBS' Prints Are All Over It

By John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT

Benzinga

FLGC: Laying the Groundwork For Global Sales of Cannabis & Related Products

By M. Marin NASDAQ:FLGC READ THE FULL FLGC RESEARCH REPORT

Benzinga

MNOV: Positive Results for MN-166 (Ibudilast) in Patients at Risk of Acute Respiratory Distress Syndrome…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

CLSN: OVATION 2 Study 85% Enrolled…

By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT

Benzinga

CANG: Q1 Results roughly inline with our lowered expectations but the Chinese auto market remains under pressure.

By Brian Lantier, CFA NYSE:CANG READ THE FULL CANG RESEARCH REPORT

Benzinga

NTRB: Revenue Growth & New Bookings Support Positive Outlook

By M. Marin NTRB:NASDAQ READ THE FULL NTRB RESEARCH REPORT

Benzinga

TLSA: Clinical Improvements for 2nd SPMS Patient

By John Vandermosten, CFA NASDAQ:TLSA Clinical Results for Second SPMS Patient

Benzinga

Read news from The Economist, FT, and more,
with one subscription

SQFT: Strengthening Balance Sheet; MURF Seeking Initial Business Combination Candidates

By M. Marin NASDAQ:SQFT READ THE FULL SQFT RESEARCH REPORT MURF IBC could create upside for SQFT

Benzinga

PKKFF: Tenet Fintech Revenues Increased 144% In Q1 Despite Delayed Plans and Seasonal Weakness

By Lisa Thompson OTC:PKKFF READ THE FULL PKKFF RESEARCH REPORT

Benzinga

EEIQ: Positive Takeaways of O&O Davis College Expanding Offerings

By M. Marin NASDAQ:EEIQ READ THE FULL EEIQ RESEARCH REPORT

Benzinga

YTRA: Yatra Online Adjusted Revenues Rebounded 51% in 2022 and Could Double in 2023 as Travel Returns to India

By Lisa Thompson NASDAQ:YTRA READ THE FULL YTRA RESEARCH REPORT

Benzinga

UCASU: Pivoting for portfolio diversity

By Beth Senko, CFA OTC:UCASU READ THE FULL UCASU RESEARCH REPORT

Benzinga

MITC: MeaTech 3D announces 1st quarter results and provides updates on technology and business developments.

By Thomas Kerr, CFA NASDAQ:MITC READ THE FULL MITC RESEARCH REPORT

Benzinga

RFHRF: Renforth Resources Continues to Advance Surimeau, an early stage polymetallic (Ni-Cu-Co-Zn) project; progress is being reported steadily on a monthly basis.

By Steven Ralston, CFA OTC:RFHRF READ THE FULL RFHRF RESEARCH REPORT

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

CFRX: Results from Interim Futility Analysis in July 2022…

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT

Benzinga

DFFN: Data from Altitude Trial Expected in June 2022…

By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT

Benzinga

SYTA: Siyata Mobile Reports 1st Quarter 2022 Results and Updates the Investor Community on Key Product Categories.

By Thomas Kerr, CFA NASDAQ:SYTA READ THE FULL SYTA RESEARCH REPORT

Benzinga

RVPH: First Quarter Results

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

BCLI: Anticipating News on How NurOwn® Will be Advanced Forward…

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT

Benzinga

EDSA: Enrollment of Phase 2b Trial of EB01 to Complete in 4Q22…

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT

Benzinga

SNGX: Phase 2a Trial of SGX302 in Psoriasis to Initiate in Second Half of 2022…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT

Benzinga

TENX: 1Q:22 Financial and Operational Review

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT

Benzinga

LPCN: OLE Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

Benzinga

DSS: DSS Adds Sharing Global Services to Its Income Statement

By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH REPORT

Benzinga

VIRI: Enrollment Complete in FORTRESS Trial; Results Expected in September 2022…

By David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.